Epstein–Barr virus peptide antigens presented on MHC class I (EBV-pMHC-I)

Epstein–Barr virus (EBV) peptide antigens presented on MHC class I molecules represent a critical immunological target for the treatment of EBV-associated malignancies and lymphoproliferative disorders. These complexes consist of short viral peptides, derived from proteins such as Latent Membrane Protein 2 (LMP2) or EBV Nuclear Antigen 1 (EBNA1), which are processed and displayed on the cell surface by Human Leukocyte Antigen (HLA) molecules. In healthy individuals, these complexes are recognized by the immune system to maintain viral latency; however, in immunocompromised patients or those with EBV-driven cancers, this surveillance fails. Therapeutic strategies targeting these pMHC complexes include adoptive T-cell therapies and T-cell receptor (TCR) engineered cells, which are designed to specifically identify and eliminate cells presenting these viral markers. The most prominent example is Tabelecleucel, an allogeneic T-cell therapy approved for EBV-positive post-transplant lymphoproliferative disorder. Because these targets are highly specific to infected or transformed cells, they offer a pathway for precision immunotherapy, though their application is strictly limited by the patient's specific HLA genotype (Citations: UniProt: P03211, PubMed: 33055371, NIH: NCT04554914).

Other names

EBV peptide-HLA complexesEpstein-Barr virus antigen-MHC class I complexEBV pMHCEBV-specific peptide-major histocompatibility complex

The primary mechanism of action involves the recognition of specific EBV peptides presented on MHC class I molecules by the T-cell receptors (TCRs) of cytotoxic T lymphocytes (CTLs). Therapeutic interventions, such as adoptive cell therapy (e.g., Tabelecleucel), utilize pre-sensitized or engineered T-cells that bind to these pMHC complexes to induce targeted lysis of EBV-infected cells or EBV-positive tumor cells (Citations: PubMed: 36513115, EMA: Ebvallo Summary of Product Characteristics).